Fortunately, the rate of grade 3-4 skin reactions during treatment with ICIs remains low, ranging from 1%-3.8%, occurring mainly with PDL1 inhibitors, which is a decrease from 10% in the previous trials 68, 69 (Figure 4B). Here, CD274 is linked to skin reaction.